13.07.2006 – 17:40
Improve the Service, Double the Retained Profit, Medify Solutions Limited Announces
Medify Solutions Limited today announces its own in-house product for roll out to the NHS.
This new capability will replace the legacy generic solution provided for Medify by Pervasic and specifically focuses on the known requirements of Healthcare professionals and the global delivery of MedifyRemote.
The development has been led by the company's NHS team working with Medify's live projects to deliver and meet the needs and expectations of Medify's healthcare clients and the patient.
This investment has been planned by the board of Medify to ensure total and complete ownership of not only the customer proposition, but also the complete IPR for all Medify applications. Furthermore, it will significantly contribute to Medify's ability to fulfil its service provider status for clients globally, enabling the core delivery of contractual services to be managed in house by Medify immediately removing third party costs.
Jonathan Bryant, Executive Chairman, said: "This development has been completed ahead of schedule and I am delighted, as are our customers, with the new MedifyRemote application approach. Not only does this provide product and corporate ownership to the company and its shareholders, but in a single move increases our revenue and profit margins two fold. Long-term objectives been achieved and short term commercial rewards have been exceeded. The team, led by new Group CEO Ian O'Reilly, will accelerate a more commercially profitable era for the company and the move into a total solutions and service provider status with our governmental and corporate clients."
This news release contains forward-looking statements that are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of such forward-looking statements. The words "estimate," "project," "intends," "expects," "believes," and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbour" provisions of the Private Securities Litigation Reform Act of 1995. For a more complete description of these and other risk factors that may affect the future performance of Medify Solutions Limited, see "Risk Factors" in the Company's Annual Report on Form 10-KSB and its other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made and the Company undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events.
For further information: Medify Press Office: